The first affiliated hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang 310003

1 studies enrolling now · 11 studies all time

What they study most

ALK-positive Advanced NSCLC, Advanced Solid Tumor, B Cell Precursor Acute Lymphoblastic Leukemia, Breast Cancer, Candidemia, Candidiasis, Invasive, Chronic Cutaneous Lupus Erythematosus, Heart Failure, Locally Advanced Unresectable or Metastatic Solid Tumor, Non Small Cell Lung Cancer, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma

Studies at this site

• A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) — Recruiting now
• A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole — Stopped early
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL — Running, not enrolling
• A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer — Running, not enrolling
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Running, not enrolling
• Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer — Running, not enrolling
• A Study of NB003 in Patients With Advanced Malignancies — Completed
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors — Stopped early